Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy
Open Access
- 20 April 2007
- journal article
- review article
- Published by Springer Nature in Cancer Gene Therapy
- Vol. 14 (7) , 599-615
- https://doi.org/10.1038/sj.cgt.7701054
Abstract
Despite setbacks in the past and apparent hurdles ahead, gene therapy is advancing toward reality. The past several years have witnessed this new field of biomedicine developing rapidly both in breadth and depth, especially for the treatment of cancer, thanks largely to the better understanding of molecular and genetic basis of oncogenesis and the development of new and improved vectors and technologies for gene delivery and targeting. This article is intended to provide a brief review of recent advances in cancer gene therapy using adenoviruses, both as vectors and as oncolytic agents, and some of the recent progress in the development of immunotoxins for use in cancer gene therapy.Keywords
This publication has 136 references indexed in Scilit:
- Immunotoxin therapy of cancerNature Reviews Cancer, 2006
- Immune Gene–Viral Therapy with Triplex Efficacy Mediated by Oncolytic Adenovirus Carrying an Interferon-γ Gene Yields Efficient Antitumor Activity in Immunodeficient and Immunocompetent MiceMolecular Therapy, 2006
- Readministration of helper-dependent adenovirus to mouse lungGene Therapy, 2006
- Antibody Conjugates and Therapeutic StrategiesMolecular Interventions, 2005
- Combination of adeno-associated virus and adenovirus vectors expressing bone morphogenetic protein-2 produces enhanced osteogenic activity in immunocompetent ratsBiochemical and Biophysical Research Communications, 2004
- Progress and problems with the use of viral vectors for gene therapyNature Reviews Genetics, 2003
- Dendritic cells reconstituted with human telomerase gene induce potent cytotoxic T-cell response against different types of tumorsCancer Gene Therapy, 2003
- Epidermal Growth Factor Receptor Targeting of Replication Competent Adenovirus Enhances Cytotoxicity in Bladder CancerJournal of Urology, 2002
- Mutations in Diphtheria Toxin Separate Binding from Entry and Amplify Immunotoxin SelectivityScience, 1987
- An adenovirus type 2 glycoprotein blocks cell surface expression of human histocompatibility class I antigensCell, 1985